Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

28/01/2021 Institutional visit to the Elena Renewable Gas Plant in Parc de l'Alba 12/01/2021 2021: the Alba synchrotron begins its mutation 30/12/2020 The Park has a new Urban Development Master Plan 29/11/2020 The director of Parc de l'Alba, Pere Solà, academic director of the new Postgraduate Course in Urban Planning and Health at the UPC School 18/11/2020 Catalan minister Ramon Tremosa visits the ALBA synchrotron and announces the creation of a public-private investment fund to improve knowledge transfer 03/11/2020 Catalonia, at the forefront of Europe in life sciences and health; the Alba synchrotron contributes to this leadership
1 2 3 4 5 6 7 8